A recent study by Zhang et al. investigated the combined treatment of pancreatic cancer cells with the dual HDAC/BET inhibitor TW9 and the chemotherapy compound gemcitabine, which is also a component of the cisplatin-based chemotherapy regimen for UC patients [58]. This evidence concerns the gene HDAC9 and familial pancreatic carcinoma.